Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 9Thoracic 4Genitourinary 4Head & Neck 3Dermatologic 3Gynecologic 2Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Melanoma 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 31Nivolumab 11Ipilimumab 6spartalizumab 5cemiplimab 5atezolizumab 5Gemcitabine 4Docetaxel 4durvalumab 3budigalimab 3avelumab 3Oxaliplatin 3Leucovorin 3Irinotecan 3Immune Checkpoint Inhibitors 3Fluorouracil 3Cyclophosphamide 3Cetuximab 3Carboplatin 3130-nm albumin-bound paclitaxel 3obinutuzumab 2lenvatinib 2fludarabine 2epacadostat 2X-Rays 2Paclitaxel 2Immunoglobulin G 2Cisplatin 2Capecitabine 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Immune Checkpoint Inhibitors × Head & Neck × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Maastricht University Medical Center

Phase 1/2 Recruiting
126 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

BioAtla, Inc.

Phase 1/2 Completed
132 enrolled
BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡